retatrutide clinical trial information ESC 2024: improves lipid and cardiovascular risk profile in Phase II retatrutide peptide | peptidesskin

The most common reported side effects are gastrointestinal nausea, vomiting, diarrhoea, and constipation consistent with GLP-1 receptor agonist class effects

FDA IND for both forms planned Q2 2026

Retatrutide is in clinical trials and likely wont be available until 2026 or 2027

A note on compounded versions As demand for these medications has surged, compounded versions of semaglutide have entered the market at lower price points

In this context, retatrutide pen is a modern research reagent being analysed in metabolic and endocrinological models

Most of what The Spa does works on the outside: the skin, the face, the surface